BLA 020563 · Lilly
Humalog Kwikpen
Insulin Lispro Recombinant · Injection · Insulin Analog
NovelLast checked: Nov 20, 2026Latest source record: May 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Jun 14, 1996
Approved uses
9
Original approval plus efficacy supplements
Registered trials
15
0 Phase 3, 0 recruiting
FAERS reports
129,052
60,658 serious, 5,766 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 18, 2026.
Insulin Lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Insulin Lispro is a rapid acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )
Mechanism: Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 14, 2012 Supplement 123 · Efficacy LetterLabel
- May 18, 2011 Supplement 105 · Efficacy LabelLetter
- Jun 2, 2004 Supplement 24 · Efficacy LabelLetter
- Oct 25, 2002 Supplement 35 · Efficacy
- Apr 4, 2000 Supplement 10 · Efficacy LabelLetter
- Apr 4, 2000 Supplement 13 · Efficacy LetterLabel
- Apr 4, 2000 Supplement 11 · Efficacy LetterLabel
- Apr 4, 2000 Supplement 12 · Efficacy LetterLabel
- Jun 14, 1996 Original approval · Type 1 - New Molecular Entity Review
5 products under this application
- HUMALOG KWIKPEN · INSULIN LISPRO RECOMBINANT 200UNITS/ML · INJECTABLE, INJECTION · Prescription
- HUMALOG PEN · INSULIN LISPRO RECOMBINANT 100 UNITS/ML · INJECTABLE, INJECTION · Discontinued
- HUMALOG TEMPO PEN · INSULIN LISPRO RECOMBINANT 100UNITS/ML · INJECTABLE, INJECTION · Prescription
- HUMALOG KWIKPEN · INSULIN LISPRO RECOMBINANT 100 UNITS/ML · INJECTABLE, INJECTION · Prescription
- HUMALOG · INSULIN LISPRO RECOMBINANT 100 UNITS/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Lispro Recombinant" as an intervention, any sponsor and status, largest first.
- CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)Pivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01848990 · 456 participants · Start Mar 2013 · Primary completion Feb 2014
Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Precommercial Hylenex recombinant (hyaluronidase human injection) and 3 more · For: Type 1 Diabetes Mellitus
Sites: Concord, California; Encino, California; Escondido, California · 39 sites in all
- Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic PatientsPivotal-lookingCompleted
Sun Yat-sen UniversityAcademic, hospital or other
NCT01147627 · 416 participants · Start Aug 2010 · Primary completion Aug 2012
Drug: exenatide injection; Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R and 1 more · For: Diabetes Mellitus, Type 2; Newly Diagnosed
Sites: Beijing, China; Guangzhou, China; Qingyuan, China · 25 sites in all
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes MellitusPivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01194245 · 135 participants · Start Aug 2010 · Primary completion Aug 2011
Drug: Insulin lispro; recombinant human hyaluronidase PH20 and 3 more · For: Diabetes Mellitus, Type 1
Sites: Escondido, California; La Jolla, California; San Mateo, California · 19 sites in all
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes MellitusPivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01194258 · 132 participants · Start Aug 2010 · Primary completion Aug 2011
Drug: Insulin lispro; Insulin aspart and 3 more · For: Diabetes Mellitus, Type II
Sites: Concord, California; Encino, California; Escondido, California · 22 sites in all
Halozyme TherapeuticsIndustry
NCT00883558 · 48 participants · Start May 2009 · Primary completion Feb 2010
Drug: Insulin Lispro; regular human insulin and 2 more · For: Diabetes Mellitus, Type 1
Sites: Aurora, Colorado; Miami, Florida; Detroit, Michigan · 8 sites in all
Halozyme TherapeuticsIndustry
NCT00803972 · 42 participants · Start Nov 2008 · Primary completion Aug 28, 2009
Drug: rHuPH20; Insulin Human Injection and 1 more · For: Healthy Volunteers
Sites: San Antonio, Texas
Halozyme TherapeuticsIndustry
NCT00705536 · 26 participants · Start Dec 2007 · Primary completion Feb 2008
Drug: Humalog; Humulin-R and 1 more · For: Diabetes Mellitus
Sites: San Antonio, Texas
Halozyme TherapeuticsIndustry
NCT01526733 · 25 participants · Start Dec 2011 · Primary completion Aug 2012
Drug: Sham Injection; Recombinant human hyaluronidase PH20 and 2 more · For: Type 1 Diabetes Mellitus
Sites: Chula Vista, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased36,329
- incorrect dose administered8,658
- blood glucose decreased8,320
- drug ineffective7,715
- visual impairment5,049
- nausea4,797
- malaise3,739
- fatigue3,696
- hypoglycaemia3,671
- fall3,343
- drug dose omission3,323
- diarrhoea3,188
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,189 |
| 2005 | 1,265 |
| 2006 | 1,680 |
| 2007 | 1,554 |
| 2008 | 1,463 |
| 2009 | 1,792 |
| 2010 | 1,841 |
| 2011 | 2,034 |
| 2012 | 2,107 |
| 2013 | 1,732 |
| 2014 | 4,580 |
| 2015 | 24,791 |
| 2016 | 8,487 |
| 2017 | 9,234 |
| 2018 | 8,994 |
| 2019 | 8,984 |
| 2020 | 9,182 |
| 2021 | 7,793 |
| 2022 | 6,793 |
| 2023 | 5,902 |
| 2024 | 5,555 |
| 2025 | 8,089 |
| 2026 | 4,011 |
Recalls
2 FDA enforcement reports for this application.
Mar 12, 2024 · Class II · Completed
CGMP Deviations
Apr 5, 2022 · Class I · Completed
TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions due to inclement weather.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Sep 1, 2026
Insulin Lispro Junior KwikPen, Injection, 100 [iU]/1 mL (NDC 0002-7752-05). A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have...
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Humalog (Insulin Lispro)
2024 spending
$98.4M
Beneficiaries
149,275
511,120 claims
Per beneficiary
$659
$6.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $449,251,292 |
| 2021 | $435,057,237 |
| 2022 | $440,789,067 |
| 2023 | $458,058,582 |
| 2024 | $98,416,547 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen.
Ignaut DA, Schwartz SL, Sarwat S, et al. · Diabetes Educ 2009 · Comparative Study, Randomized Controlled Trial
- Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin.
Wang T, Conrad KA, van Brunt K, et al. · J Diabetes Sci Technol 2016 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Ease of use and patient preference injection simulation study comparing two prefilled insulin pens.
Clark PE, Valentine V, Bodie JN, et al. · Curr Med Res Opin 2010 · Multicenter Study, Randomized Controlled Trial
Sponsor: Eli Lilly · Also marketed as Humalog Pen, Humalog Tempo Pen, Humalog
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.